Regular use of COX-2 inhibitors reduces breast cancer risk

September 16, 2015

Non-selective COX-2 inhibitors, such as aspirin and ibuprofen, also reduced the risk of breast cancer. This study highlights the potential of nonsteroidal anti-inflammatory drugs (NSAIDs) for the prevention of breast cancer.

Randall Harris and colleagues from The Ohio State University College of Medicine and Public Health, Columbus, Ohio, USA, collected data on 323 patients with invasive breast cancer shortly after their diagnosis. Harris et al. matched the patients for age, race and county of residence with 649 control individuals with no personal history of cancer. Data collected for patients and controls included information on breast cancer risk factors, and the use of selective COX-2 inhibitors and other NSAIDs.

Harris et al.??s results show that selective COX-2 inhibitors, as a group, were associated with a significantly reduced risk of breast cancer (OR=0.29) when taken daily for at least two years: a daily dose of 200 mg celecoxib reduced the risk of breast cancer by 83% and a daily dose of 25 mg rofecoxib reduced the risk of breast cancer by 64%. Regular use of non-selective COX-2 inhibitors - aspirin (325 mg), ibuprofen (200mg) and naproxen (250 mg) ?? also significantly reduced the risk of breast cancer, but less so than regular intake of selective COX-2 inhibitors. Ibuprofen and aspirin significantly decreased the risk of developing breast cancer when taken at least every other day for at least five years. Regular intake of acetaminophen, an analgesic lacking COX-2 activity, had no effect on the risk of breast cancer.


"Smart German chemists have been working on Remifemin for over 50 years," says Yale University School of Medicine Clinical Professor Mary Jane Minkin, MD, who recommends Remifemin as a standard alternative to HRT. "While its mechanism of action is unclear, black cohosh is one of the few products that seems to relieve hot flashes. Twenty percent of patients sail through menopause without problems, but eighty percent have varying degrees of symptoms, some severe," she explains. "I talk to everyone about Remifemin, along with lifestyle issues like healthy diet and exercise. I respect the personal preferences of my patients, many of whom do not want drug intervention." Dr. Minkin is author of A Woman's Guide to Menopause & Perimenopause (Yale University Press 2005).

Not all black cohosh is the same. Most products in the market lack the standardization and research that can ensure efficacy and safety, and multi- ingredient compounds can potentially create problems from drug interactions. "Remifemin, with over 90 scientific papers, is the most researched black cohosh product in the world," explains Matt Schueller, Senior VP Marketing for Enzymatic Therapy, Inc., exclusive distributors of Remifemin in North America and one of the first to introduce standardization to the U.S. supplement industry. "Comprising a proprietary, standardized extract (uniform dosage) of pure black cohosh root called RemiSure, it is the #1 OB/GYN-recommended non-prescription menopause therapy."